March Biosciences is a clinical-stage company specializing in cell therapy, particularly through the development of CAR-T cell strategies aimed at treating challenging hematological cancers. Their flagship product, MB-105, is a CD5 CAR T-cell therapy currently in clinical development for T-cell lymphoma. The company emphasizes a unique approach that combines biological and engineering insights to unlock new target spaces without the complexities and risks associated with additional gene editing. This innovative strategy aims to enhance the efficacy of their therapies while minimizing potential side effects.

In addition to their focus on target unlocking, March Biosciences prioritizes cell quality and manufacturing efficiency. The company is committed to ensuring that their CAR T-cells achieve peak functionality by reducing cell manipulations during production. They have established a streamlined manufacturing process designed to deliver consistent and robust production of high-quality CAR T-cells. With a seasoned leadership team boasting over 20 years of experience in the cell therapy field, March Biosciences is dedicated to transforming patient care by addressing the limited therapeutic options available for patients with relapsed or refractory T-cell lymphoma.

United States

March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

March Biosciences

Company Details